Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats

Hypertension
Renhui YangHongkui Jin

Abstract

Vascular endothelial growth factor (VEGF) induces hypotension in normotensive subjects, which is considered to be a major side effect for treatment of ischemic diseases. However, the hypotensive effect of VEGF has not been investigated in the setting of hypertension. This study determined effects of VEGF on hemodynamics, pharmacokinetics, and release of NO and prostaglandin I2 (PGI2) in vivo and on vasorelaxation of mesentery artery rings in vitro in spontaneously hypertensive rats (SHR) compared with Wistar-Kyoto rats (WKY). Intravenous infusion of VEGF for 2 hours produced a dose-related decrease in arterial pressure, which was enhanced in conscious SHR compared with WKY (P<0.01), and an increase in heart rate in WKY but not in SHR. In response to similar doses of VEGF, compared with WKY, SHR had a higher plasma VEGF level and lower VEGF clearance (P<0.01). Circulating NO and PGI2 levels after VEGF administration were not increased in SHR versus WKY, and VEGF-induced vasorelaxation was blunted in SHR versus WKY in vitro, suggesting endothelial dysfunction in SHR. One-week VEGF infusion also caused greater hypotension (P<0.05) in the absence of tachycardia in SHR compared with WKY controls. Thus, despite blunted vasorelaxation...Continue Reading

References

Aug 1, 1992·Clinical and Experimental Pharmacology & Physiology·G A Head, M A Adams
Nov 1, 1989·The Journal of Clinical Investigation·D T ConnollyJ Feder
Jun 1, 1986·The American Journal of Physiology·E T PoehlmanC Bouchard
Jun 1, 1995·Hypertension Research : Official Journal of the Japanese Society of Hypertension·P M Vanhoutte, C M Boulanger
Oct 1, 1994·Clinical and Experimental Pharmacology & Physiology·G A Head
Apr 29, 1994·Biochemical and Biophysical Research Communications·A M LeoneS Moncada
Jun 1, 1996·The Journal of Surgical Research·M D HariawalaJ F Symes
Jun 1, 1996·Journal of Cardiovascular Pharmacology·R YangH Jin
Feb 1, 1997·Endocrine Reviews·N Ferrara, T Davis-Smyth

❮ Previous
Next ❯

Citations

Dec 21, 2004·Angiogenesis·David C SaneK Bridget Brosnihan
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
Jan 31, 2003·The Journal of Clinical Hypertension·Thomas G Pickering
Apr 16, 2011·Journal of Pregnancy·Janina Müller-Deile, Mario Schiffer
Aug 30, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrew AdvaniRichard E Gilbert
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elizabeth L Strevel, Lillian L Siu
Jul 22, 2014·Stem Cell Research·Kathy O LuiKenneth R Chien
Jul 3, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Sihyung YangEuichaul Oh
Jul 18, 2008·Supportive Cancer Therapy·Yull Arriaga, Carlos R Becerra
Apr 18, 2018·Tissue Engineering. Part a·Siddharth PatelLuiz E Bertassoni
Aug 3, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Orsolya PéterfiLászló Bába

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.